QUREIGHT NAMES DR STEVEN BISHOP CHIEF MEDICAL OFFICER TO DRIVE GLOBAL CLINICAL TRIAL DELIVERY
Qureight has appointed Dr Steven Bishop as its new Chief Medical Officer, as the fast-growing techbio company sharpens its focus on scaling global clinical trials and advancing AI-driven imaging biomarkers for lung and heart disease.
The appointment follows a period of sustained commercial momentum for the company, which applies artificial intelligence to CT imaging and clinical data to improve the speed, precision and reliability of clinical trials. Dr Bishop, who previously served as Qureight’s Chief Data Officer, will now take responsibility for clinical operations, product development and clinical strategy, reflecting a broader evolution in the company’s structure as it grows.
In his new role, Dr Bishop will oversee the Clinical Operations team responsible for delivering multinational studies for pharmaceutical and biotech clients. He will also lead Quality Assurance and Regulatory Affairs, while working closely with business development colleagues to ensure that Qureight’s platform continues to meet the needs of an increasingly data-driven clinical trials market.
Dr Bishop brings more than two decades of experience across healthcare, data science and artificial intelligence. His career spans both medtech and healthtech, with published research in critical care pathophysiology and surgical data science. During his tenure as Chief Data Officer, he was responsible for ensuring that Qureight’s AI models and imaging biomarkers were trained on high-quality datasets, while expanding the company’s global network of data partnerships across NHS Trusts, hospital groups, contract research organisations and industry.
Before joining Qureight, Dr Bishop held senior leadership roles at CMR Surgical, where he was Head of Research and Strategy, and at Flok Health, where he served as Director of Clinical, Regulatory and AI. He holds an undergraduate degree in computer science and a medical degree from the University of Cambridge, and has completed specialist training in anaesthesia and intensive care medicine. He is also a Fellow of the Royal College of Anaesthetists.
Commenting on the appointment, Muhunthan Thillai, co-founder and chief executive of Qureight, said:
“Steven has proven himself to be an invaluable member of the Qureight leadership team since he joined 18 months ago. His new role as CMO is reflective both of the progress of the company, and of his significant contributions to our success. Our team now has the infrastructure, operational processes, capability and compliance to lead global clinical studies. I look forward to working with him in his new role to grow and develop Qureight further to become an imaging world leader for clinical trials.”
Dr Bishop said the move reflects both the maturity of the platform and its potential impact on patients:
“I first joined Qureight as it was clear that the potential impact of the platform, to support clinical trials and ultimately increase treatment options for patients, was huge. It has been a real pleasure to work with such a committed and knowledgeable team over the past 18 months, and I’m both delighted and excited to be moving into this new role.”
The appointment underscores the growing importance of advanced imaging analytics and AI-powered data platforms as drug developers seek faster, more reliable ways to evaluate new therapies in an increasingly complex regulatory and clinical environment.
